A Bioactive PLGA-modified SIS scaffold loaded with astragaloside IV–preconditioned BMSCs promotes infected wound healing Authors: Xilai Hu, Yuhao Wu, Yaqian Chen, Xiaowen Li, Hai Huang Published: 2026 ABSTRACT Infected wounds present a significant clinical challenge due to persistent inflammation, bacterial infection, and hindered tissue regeneration. In this study, we developed a composite bioactive scaffold by combining PLGA-modified small intestinal submucosa (SIS) with astragaloside IV (AS-IV)–preconditioned bone marrow mesenchymal stem cells (BMSCs). We evaluated its physicochemical characteristics and therapeutic effectiveness both in vitro and in a infected wound model. The composite scaffold exhibited enhanced mechanical strength and facilitated the adhesion and proliferation of the BMSCs. Pretreatment with AS-IV significantly enhanced BMSC survival and boosted the secretion of pro-regenerative factors such as VEGF and TGF-β, potentially contributing to the observed enhanced regenerative effects in this study. In vivo, the PABS group exhibited markedly accelerated wound closure compared to the control groups, along with reduced infiltration of inflammatory cells and increased collagen deposition (~ 50%) and epidermal thickness (~ 154 μm). Furthermore, enhanced angiogenesis and controlled expression of inflammatory cytokines (reduced TNF-α, IL-1β, and IL-6; increased IL-10) were observed, suggesting a potentially improved modulation of the wound microenvironment. This multifunctional scaffold facilitated wound healing by combining antibacterial, anti-inflammatory, and pro-regenerative effects, offering a promising approach for managing chronic and infected wounds.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-54964-5. Introduction Chronic and infection-associated wounds present significant clinical challenges, characterized by persistent bacterial colonization, heightened inflammation, and impaired tissue regeneration. These issues are commonly seen in diabetic ulcers, pressure injuries, and postoperative infections, resulting in prolonged healing periods and a considerable healthcare burden1,2. Such wounds impact millions of patients globally, leading to substantial morbidity, extended hospital stays, and escalated healthcare expenses. Despite progress in existing treatments such as debridement, antibiotic use, and traditional wound dressings, treatment efficacy remains inadequate3. Hence, there is an urgent need for multifunctional therapeutic approaches that can effectively manage infections and facilitate tissue regeneration simultaneously. Biomaterial-based scaffolds derived from the extracellular matrix (ECM), such as small intestinal submucosa (SIS), exhibit significant potential due to their excellent biocompatibility and structural resemblance to native tissues. However, the use of SIS in infected wounds is hindered by its inadequate mechanical strength and absence of inherent antibacterial properties4–6. Recent studies have increasingly concentrated on enhancing ECM-based scaffolds by modifying their structure and integrating bioactive components to boost their performance in intricate wound environments7,8. To tackle these challenges, synthetic polymers such as poly(lactic-co-glycolic acid) (PLGA) have been introduced to improve structural stability and durability. Research has shown that aligned PLGA/SIS composite nanofibrous scaffolds offer substantial promise for tendon tissue engineering because of their biomimetic anisotropic structure that guides cell alignment, along with the complementary mechanical and cytocompatible properties of their constituent materials7. The regenerative and immunomodulatory properties of mesenchymal stem cells (MSCs) have been extensively studied. However, their therapeutic effectiveness is often compromised in the hostile inflammatory microenvironment of infected wounds, significantly restricting their clinical application4,6. Recent studies have shown that astragaloside IV (AS-IV), a bioactive compound extracted from Astragalus membranaceus, enhances survival, proliferation, and paracrine activity of MSCs under oxidative and inflammatory stress9–13. The preconditioning of MSCs with AS-IV is suggested as a promising therapeutic strategy14–22. However, limited research has combined AS-IV–preconditioned MSCs with structurally optimized ECM-based scaffolds for the treatment of infected wounds, leaving the potential synergistic effects of this combined system largely unexplored. In this study, we propose a novel multifunctional strategy of integrating PLGA-modified SIS with AS-IV-preconditioned bone marrow mesenchymal stem cells (BMSCs). Unlike prior approaches that focused solely on scaffold modification, stem cell therapy, or drug delivery, our study introduces a coordinated strategy that integrates structural reinforcement, cellular activation, and pharmacological preconditioning within a single system. This approach aims to address multiple pathological factors of infected wounds simultaneously. We systematically evaluated the physicochemical properties, biological performance, and therapeutic efficacy in an infected wound model. This study not only introduces a previously underexplored combinational approach but also provides new insights into the rational design of multifunctional biomaterials, offering a promising strategy for the clinical management of infected and chronic wounds. Methods Materials and animals Astragaloside IV (standard grade; Yuanye Bio, Shanghai, China), PLGA nanoemulsion (prepared in our laboratory following previously described methods23, decellularized porcine small intestinal submucosa (SIS; prepared in our laboratory following previously described methods23, rat BMSCs (prepared in our laboratory following previously described methods23, murine macrophage cell line RAW264.7 (Cell Bank, Chinese Academy of Sciences, Shanghai, China), rat fibroblast L929 cells (Solarbio, Beijing, China), human umbilical vein endothelial cells (HUVECs; Solarbio, Beijing, China), Staphylococcus aureus (ATCC 43300; Luwei Biotechnology, Shanghai, China), Escherichia coli (ATCC 25922; lab-preserved), lipopolysaccharide (LPS; E. coli O111:B4, Sigma-Aldrich, USA), ELISA kits for TNF-α, IL-1β, IL-6, and IL-10 (Meilian Bio, Shanghai, China), PrimeScript™ RT Master Mix (RR036; Takara, Japan), 4% paraformaldehyde solution, crystal violet solution (Beyotime, China), TB Green® Premix Ex Taq™ II (RR820; Takara, Japan), and a modified Masson’s trichrome staining kit (Solarbio, Beijing, China) were utilized in this study. All experiments were performed using deionized water, unless otherwise specified. The animals were euthanized by CO₂ inhalation. Twenty-five healthy male Sprague–Dawley (SD) rats (SPF grade, 200–220 g) were acquired from SLAC Laboratory Animal Co., Ltd. (Shanghai, China). The animals were housed at the Animal Facility of Zhejiang Chinese Medical University (SYXK [Zhe] 2018-0012). All animal procedures were approved by the Institutional Animal Care and Use Committee of Zhejiang Chinese Medical University. Preparation of AV-BMSC-PLGA-SIS (PABS) material Preparation and characterization of PLGA nanoparticles PLGA (0.4 g) was dissolved in a mixed organic solvent comprising acetone and chloroform (9:6, v/v) in a fume hood. The resulting solution was slowly added to 40 mL of deionized water while stirring magnetically at 400 rpm for 30 min to create an emulsion. Subsequently, the organic solvent was eliminated using a rotary evaporator. The nanoparticle suspension was then harvested through centrifugation at 12,000 rpm. The particle size distribution was assessed using a laser particle size analyzer, and the morphological characteristics were observed via transmission electron microscopy (TEM). The concentration of the nanoparticle suspension was determined utilizing the dry-weight method23. Preparation of PLGA-SIS (PS) Porcine small intestines were harvested from healthy pigs (~ 6 months old, ~ 100 kg) within 4 h. The mucosal and muscle layers were removed to isolate the submucosa, which was then washed with sterile saline to obtain the SIS24,25. The obtained SIS was decellularized, freeze-dried, sterilized, and trimmed to the desired size. For PLGA modification, SIS samples were placed in 6-well plates, exposed to the PLGA nanoemulsion, and incubated at 37 °C with 5% CO₂ for 24 h26. Following incubation, the cells were rinsed twice with PBS to eliminate any residual nanoparticles. Preparation of PABS composite and conditioned medium AS-IV-treated BMSCs were seeded on PLGA–SIS scaffolds (2 × 10⁶ cells/cm²) and incubated at 37 °C with 5% CO₂ for 4 h. Subsequently, low-glucose DMEM containing 160 µM AS-IV was added23,27,28. After 48 h, the medium was replaced with fresh complete medium for continuous culture. Five groups were established: normal (NOR), PLGA-SIS (PS), BMSCs only (BMSC), AS-IV-treated BMSCs (AB), BMSCs on PLGA–SIS (BPS), and AS-IV-treated BMSCs on PLGA–SIS (PABS). After 48 h of incubation, the supernatant was collected for further analysis. For the SIS-only group, samples were cut and soaked in PLGA–PBS with shaking for 48 h, then filtered (10 kDa cutoff, 4500 g, 30 min, 4 °C), and stored at − 80 °C. Characterization of AV-BMSC-PLGA-SIS materials Scanning electron microscopy The surface morphologies of the SIS and PLGA–SIS scaffolds were analyzed through scanning electron microscopy (SEM; Hitachi SU8100, Japan). The samples were fixed in 2.5% glutaraldehyde at 4 °C for 24 h, washed, and dehydrated using a graded ethanol series. Subsequently, the samples were dried, sputter-coated with gold, and imaged at an accelerating voltage of 5.0 kV. Mechanical tensile testing The tensile properties of SIS, PS, and PABS scaffolds were assessed utilizing a universal testing machine (Instron 5943, USA). Rectangular samples (20 mm × 10 mm) were immersed in PBS for 1 h before the evaluation. The crosshead speed was adjusted to 10 mm/min. Stress–strain curves were generated to determine the tensile strength and Young’s modulus. Degradation test Scaffolds (n = 3 per group) were incubated in PBS (pH 7.4) containing 0.2 mg/mL lysozyme at 37 °C. Samples were collected daily from days 1 to 7, washed, freeze-dried, and weighed. The degradation rate was calculated as the percentage of mass loss relative to the initial dry weight. Nanoparticle size test The size distribution and polydispersity index of the PLGA nanoparticles were analyzed using dynamic light scattering (DLS) with a Zetasizer Nano ZS90 (Malvern Instruments, UK). The nanoparticles were dispersed in deionized water, and measurements were conducted at 25 °C. In vitro biological evaluation of the scaffold Tube formation test HUVECs (2 × 10⁴ cells per well) were seeded on Matrigel-coated 96-well plates and treated with scaffold extracts (Control, PS, BMSC, AB, BPS, PABS). After 6 h at 37 °C, tube formation was observed under an inverted microscope (Olympus IX71, Japan). Tube length and node number were measured using ImageJ software with an angiogenesis analyzer plugin. Scratch test L929 fibroblasts were cultured in 6-well plates until approximately 90% confluence was achieved. A direct scratch was created using a 200 µL pipette tip, followed by washing the wells with PBS. Subsequently, serum-free medium enriched with extracts from the six groups was introduced. Images were taken at 0 and 24 h using a phase-contrast microscope. The rate of migration was determined by measuring the percentage of wound closure through ImageJ software. Immunofluorescence staining for collagen I and III BMSCs were seeded on glass coverslips in 24-well plates and cultured in a scaffold-conditioned medium. After 72 h, the cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, and blocked with 5% BSA. Subsequently, the cells were incubated overnight at 4 °C with primary antibodies for collagen I and collagen III. Following washing, Alexa Fluor-conjugated secondary antibodies and DAPI were added. The visualization of the cells was performed using a fluorescence microscope. ELISA test for secreted cytokines RAW264.7 macrophages were cultured in 96-well plates and allowed to adhere overnight. The cells were exposed to LPS (10 ng/mL in high-glucose DMEM containing 2% FBS) for 24 h. Following a PBS wash, sterile-filtered extracts (0.22 μm) were added and adjusted to 200 µL per well with fresh medium. For dose-response assessments, six concentrations (0%–100% v/v) were utilized for the PS, B, BPS, and PABS groups in triplicate. A single concentration was employed for all six groups for inter-group comparisons. After 24 h, supernatants were collected and analyzed for TNF-α, IL-1β, IL-6, and IL-10 using ELISA kits from Shanghai Enzyme-Linked Bio. Absorbance readings were taken at 450 nm (reference: 570–620 nm). Cytokine levels were determined using standard curves. The CCK-8 assay confirmed cell viability exceeding 80% and ruled out cytotoxic effects. qPCR test qPCR was conducted using SYBR Green on a real-time PCR system. Each 20 µL reaction included 10 µL Master Mix, 1 µL cDNA (~ 50 ng RNA), 0.4 µM primers, and nuclease-free water. The thermal cycling steps were: 95 °C for 30 s, followed by 40 cycles of 95 °C for 5 s and 60 °C for 30 s. A melt curve (65–95 °C, 0.5 °C steps) was used to confirm single peaks. The No Reverse Transcription and No Reverse Transcriptase Control controls exhibited no amplification. Primer efficiency (90%–110%, R² ≥ 0.99) was validated using standard curves. Data analysis was performed using the 2−ΔΔCt method. Antibacterial activity test Five sterile-filtered extracts (Con, PS, BMSC, BPS, PABS) were combined with a suspension of Staphylococcus aureus (10⁴ CFU/150 µL) in a 3:1 ratio and then applied to 96-well plates (200 µL per well). Controls with only bacteria and blanks were also prepared. Following incubation at 37 °C for 12–18 h, the optical density (OD₆₀₀) was determined. Inhibition rate (%) = (OD₍NOR₎ – OD₍Sample₎) / (OD₍NOR₎ – OD₍Blank₎) × 100%. Plate counting validated the OD results. The data were presented as mean ± standard deviation (SD) and analyzed through one-way analysis of variance (ANOVA) with Tukey’s post hoc test. Assessments of in vivo repair Infected wound model setup All animals were housed at the Laboratory Animal Center of Zhejiang Chinese Medical University (SYXK [Zhe] 2018-0012). The university’s Ethics Committee approved all experimental procedures. An infected full-thickness wound model was created by shaving the dorsal hair, disinfecting the skin, and making a circular excision (approximately 2 cm in diameter) along the midline. A 50 µL suspension of Staphylococcus aureus (1 × 10⁸ CFU in PBS) was applied to the wound and left for 30 min at room temperature to induce infection. Subsequently, the mice were randomly divided into four groups and treated with CON, PS, BPS, or PABS, followed by sterile dressing coverage. In vivo wound healing test The dressings were replaced every two days under sterile conditions. Wound images were taken with a digital camera at consistent distances and lighting conditions. The wound area was assessed using ImageJ software, and the healing rate (%) was calculated as follows: \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$${\text{Wound closure rate }}\left( \% \right){\text{ }} = {\text{ }}\left( {{\mathrm{W}}_{0} {\text{ }}{-}{\text{ W}}_{t} } \right){\text{ }}/{\text{ W}}_{0} \times {\text{ 1}}00\% ,$$\end{document} where W₀ is the initial wound area and Wt represents the wound area at each time point, wound healing progress was observed up to day 14 to compare between groups. H&E and Masson’s trichrome staining All animals were euthanized on day 14. Wound tissues, including the adjacent skin, were collected and fixed in 10% neutral buffered formalin for 24–48 h, dehydrated, and embedded in paraffin. Section (4 μm thick) were cut from the wound center. H&E staining was employed to assess inflammation, granulation tissue, and re-epithelialization, while Masson’s trichrome staining was utilized to visualize collagen deposition. Histological images were captured using a light microscope, and the counts of inflammatory cells and collagen area were quantified through ImageJ software. Immunohistochemical analysis Immunohistochemistry for CD31, VEGF-A, and TNF-α was conducted on 4-µm paraffin-embedded wound sections. Following deparaffinization and rehydration, antigen retrieval was carried out in citrate buffer (pH 6.0) for 20 min. Subsequently, endogenous peroxidase was blocked using 3% H₂O₂, and non-specific binding was prevented with 5% serum. Sections were incubated overnight at 4 °C with primary antibodies against CD31, VEGF-A, and TNF-α, followed by incubation with HRP-conjugated secondary antibodies for 30 min at 25 °C. DAB was utilized for color development, and hematoxylin was employed for nuclear staining. Subsequently, images were captured using a light microscope, and marker expression along with microvessel density was quantified using ImageJ software. Statistical analysis All quantitative data are expressed as the mean ± SD obtained from at least three independent experiments (n ≥ 3). Statistical analyses were performed using GraphPadPrism10.0 (GraphPadSoftware, San Diego, CA, USA). The Shapiro–Wilk test was first applied to verify data normality. For multiple-group comparisons, ANOVA followed by Tukey’s post hoc test was employed, and comparisons between groups were analyzed using the two-tailed unpaired Student’s t-test. Differences were considered statistically significant at P < 0.05. Statistical significance was determined as follows: *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. All experiments were independently repeated at least three times to ensure the reproducibility and reliability of the results. Results Preparation and characterization of PABS The entire fabrication process, which involves harvesting porcine small intestine, decellularizing SIS, and modifying PLGA to create the composite scaffold, is illustrated in Fig. 1A–C. The PLGA nanoparticles exhibited a uniform distribution and a spherical morphology when observed under TEM (Fig. 1D). The size distribution analysis revealed diameters ranging from 100 to 160 nm (Fig. 1G). The decellularized SIS retained its porous and interconnected network structure (Fig. 1E). Upon the addition of PLGA nanoparticles and AS-IV-treated BMSCs, the composite scaffold (PABS) displayed distinct particle attachment on its surface (Fig. 1F). Over the 7-day in-vitro degradation test, all samples exhibited a gradual decrease in weight (Fig. 1H). Notably, SIS degraded most rapidly, while PABS maintained a higher remaining mass compared to SIS throughout the testing period. The compression curves indicated that PP possessed the highest mechanical strength (Fig. 1I). Although PABS showed a lower load-bearing capacity than PP, it still demonstrated noticeable elasticity and resistance to compression. Fig. 1Preparation and characterization of PABS material. (A-C) Fabrication process of SIS patch, including small intestine harvesting, decellularization, and final appearance. (D) TEM image of PLGA nanoparticles (scale bar = 200 nm). (E-F) SEM images of ASIV-BMSC-PLGA-SIS scaffolds (scale bars = 1 mm and 10 μm). (G) DLS particle size distribution of PLGA nanoparticles. (H) In vitro degradation profiles of scaffolds, (n = 3; ****p < 0.0001). (I) Stress–strain curves of SIS, PP, PLGA–SIS, and PABS scaffolds. Preparation and characterization of PABS material. (A-C) Fabrication process of SIS patch, including small intestine harvesting, decellularization, and final appearance. (D) TEM image of PLGA nanoparticles (scale bar = 200 nm). (E-F) SEM images of ASIV-BMSC-PLGA-SIS scaffolds (scale bars = 1 mm and 10 μm). (G) DLS particle size distribution of PLGA nanoparticles. (H) In vitro degradation profiles of scaffolds, (n = 3; ****p < 0.0001). (I) Stress–strain curves of SIS, PP, PLGA–SIS, and PABS scaffolds. In vitro angiogenesis and cell migration assay The endothelial cells formed typical capillary-like structures under various treatment conditions (Fig. 2A). In comparison to the control and PS groups, the groups treated with BMSC, AB, and BPS exhibited higher numbers of tube-like connections and branch nodes. The PABS group demonstrated the most continuous and dense network structures. Quantitative analysis verified that the total tube length and the number of junctions were notably greater in the PABS group than in the other groups (Fig. 2D–F). Fig. 2In vitro angiogenesis and cell migration assay. (A) Representative images of the tube formation assay (scale bar = 200 μm). (B) Representative images of the scratch wound healing assay at 0 h and 24 h (scale bar = 200 μm). (C) Quantitative assessment of the wound closure rate. (D) Quantitative evaluation of branch number, (E) total tube length, and (F) total node number. (n = 3, *p < 0.01, **p < 0.001, ***p < 0.0001). (The previously duplicated subfigure has been corrected, and the corresponding raw data are provided in the Supplementary Materials.) In vitro angiogenesis and cell migration assay. (A) Representative images of the tube formation assay (scale bar = 200 μm). (B) Representative images of the scratch wound healing assay at 0 h and 24 h (scale bar = 200 μm). (C) Quantitative assessment of the wound closure rate. (D) Quantitative evaluation of branch number, (E) total tube length, and (F) total node number. (n = 3, *p < 0.01, **p < 0.001, ***p < 0.0001). (The previously duplicated subfigure has been corrected, and the corresponding raw data are provided in the Supplementary Materials.) Cell migration was observed at 0 and 24 h after scratching (Fig. 2B). In both the control and PS groups, the wound area remained unhealed after 24 h. In contrast, cells treated with BMSC, AB, and BPS showed increased migration towards the scratched area. The PABS group demonstrated the most rapid wound closure, nearly fully covering the wound at 24 h. Statistical analysis revealed a marked increase in both migration distance and the number of migrated cells in the PABS group compared to other treatments (Fig. 2C). Collagen immunofluorescence staining To examine the impact of the PABS scaffolds on ECM synthesis, immunofluorescence images were utilized to illustrate the distribution of collagen I and collagen III in fibroblasts subjected to various treatments (Fig. 3A–B). In the control group, collagen I and collagen III exhibited moderate fluorescence intensity. Conversely, cells cultured with PABS exhibited enhanced green fluorescence and more concentrated staining, suggesting augmented collagen deposition. DAPI staining verified consistent nuclear distribution in both groups. Fig. 3Collagen immunofluorescence and quantification. (A) Immunofluorescence images of type I collagen. (B) Immunofluorescence images of type III collagen. Scale bar = 200 μm. Collagen immunofluorescence and quantification. (A) Immunofluorescence images of type I collagen. (B) Immunofluorescence images of type III collagen. Scale bar = 200 μm. In vitro inflammatory factor expression and antibacterial assay The levels of pro-inflammatory cytokines were assessed using qRT-PCR (Fig. 4A–F). Following LPS stimulation, mRNA levels of IL-1β, iNOS, IL-6, and TNF-α in macrophages were substantially higher compared to the control group. Subsequent treatment with various hydrogels led to a significant decrease in these cytokine levels, with the PABS group showing the lowest expression. In contrast, the mRNA levels of the anti-inflammatory cytokine IL-10 were higher in the PABS group than in the other groups. Additionally, TGF-β expression increased following PABS treatment. Fig. 4In vitro expression of inflammatory factors and antibacterial assay. (A–F) RT-qPCR analysis of polarization-related gene expression in RAW264.7 cells. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. (G) ELISA quantification of IL-6, IL-1β, TNF-α, and IL-10. Groups B, BPS, and PABS vs. SIS group: *p < 0.05, **p < 0.01; groups BPS and PABS vs. B group: ▲p < 0.05, ▲▲p < 0.01; PABS vs. BPS group: ⋆p < 0.05, \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\star\star$$\end{document}p < 0.01. (H-I) Antibacterial assays against Staphylococcus aureus and Escherichia coli (n = 3). In vitro expression of inflammatory factors and antibacterial assay. (A–F) RT-qPCR analysis of polarization-related gene expression in RAW264.7 cells. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. (G) ELISA quantification of IL-6, IL-1β, TNF-α, and IL-10. Groups B, BPS, and PABS vs. SIS group: *p < 0.05, **p < 0.01; groups BPS and PABS vs. B group: ▲p < 0.05, ▲▲p < 0.01; PABS vs. BPS group: ⋆p < 0.05, \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\star\star$$\end{document}p < 0.01. (H-I) Antibacterial assays against Staphylococcus aureus and Escherichia coli (n = 3). ELISA results revealed consistent trends at the protein level (Fig. 4G). The secretion of IL-6, IL-1β, and TNF-α was markedly inhibited in macrophages exposed to PABS, whereas IL-10 levels increased compared to the LPS-only group. The antibacterial activities of the different materials were tested against E. coli and S. aureus (Fig. 4H–I). No significant differences in E. coli inhibition were observed between the groups. However, the PABS group exhibited a slight but measurable reduction in S. aureus growth compared to the PS group. In vivo evaluation infected wound healing and histological analysis An infected full-thickness wound model in rats was successfully established and treated every two days following the experimental schedule (Fig. 5A). Representative wound images from the 14-day period are shown in Fig. 5B. Both the control and PS groups displayed visible exudation and incomplete closure, while the BPS and PABS groups showed smaller wound areas and smoother surfaces. Quantitative analysis indicated a gradual wound closure in all groups, with the PABS group demonstrating the highest wound closure rate on day 14. Fig. 5In vivo infected wound healing assay. (A) Schematic of the full-thickness infected wound model and treatment procedure. (B) Representative macroscopic images of wound healing on days 0, 3, 7, 10, and 14. Scale bar = 10 mm. Wound tracing and size quantification at various time points. Scale bar = 20 mm. Quantification of wound closure percentage. ***p < 0.001, ****p < 0.0001; n = 5. (C) H&E staining of regenerated skin tissues, with magnified insets. Scale bars = 2 mm (upper) and 200 μm (lower). Quantification of epidermal thickness. (D) Masson’s trichrome staining with magnified insets. Scale bars = 2 mm (upper) and 200 μm (lower). Quantification of collagen deposition. **p < 0.01, ***p < 0.001, ****p < 0.0001; n = 3. In vivo infected wound healing assay. (A) Schematic of the full-thickness infected wound model and treatment procedure. (B) Representative macroscopic images of wound healing on days 0, 3, 7, 10, and 14. Scale bar = 10 mm. Wound tracing and size quantification at various time points. Scale bar = 20 mm. Quantification of wound closure percentage. ***p < 0.001, ****p < 0.0001; n = 5. (C) H&E staining of regenerated skin tissues, with magnified insets. Scale bars = 2 mm (upper) and 200 μm (lower). Quantification of epidermal thickness. (D) Masson’s trichrome staining with magnified insets. Scale bars = 2 mm (upper) and 200 μm (lower). Quantification of collagen deposition. **p < 0.01, ***p < 0.001, ****p < 0.0001; n = 3. H&E staining (Fig. 5C) showed continuous epidermal regeneration in all treated wounds. The PABS group showed the thickest regenerated epidermis, measuring approximately 154 μm. Masson’s Trichrome staining (Fig. 5D) revealed blue-stained collagen fibers in the dermal layer across all groups. The PABS group exhibited a denser distribution of collagen, with a collagen-positive area of approximately 50%, surpassing that of the control, PS, and BPS groups. Immunohistochemical analysis of wound tissues Immunohistochemical staining of wound sections for CD31, VEGF, and TNF-α is shown in Fig. 6A–C. CD31 staining revealed brown vascular structures dispersed in the granulation tissue across all groups. The count of CD31-positive microvessels was highest in the PABS group, followed by the BPS, PS, and control groups. VEGF staining revealed yellow-brown cytoplasmic signals within the wound tissues. The quantitative IHC scores for VEGF were the lowest in the PABS group compared to the other groups. TNF-α staining manifested as brownish-yellow signals in inflammatory regions. The PABS group demonstrated the lowest TNF-α IHC score among all groups. Fig. 6(A) IHC staining and quantification of CD31, (B) IHC staining and quantification of VEGF, (C) IHC staining and quantification of TNF-α (E-F). **p < 0.01, ***p < 0.001, ****p < 0.0001. (A) IHC staining and quantification of CD31, (B) IHC staining and quantification of VEGF, (C) IHC staining and quantification of TNF-α (E-F). **p < 0.01, ***p < 0.001, ****p < 0.0001. Discussion Treating infected wounds presents a significant clinical challenge due to the intricate interplay among bacterial invasion, persistent inflammation, and impaired tissue regeneration. To tackle these challenges, we developed a PLGA-modified SIS scaffold incorporating astragaloside IV (AS-IV)-preconditioned BMSCs. Unlike traditional methods relying on direct drug integration, our approach involves cellular preconditioning, potentially enhancing cell survival, stress tolerance, and paracrine activity pre-implantation. Direct drug loading often faces limitations such as burst release and inadequate cellular modulation, which could compromise long-term therapeutic efficacy. study demonstrated that the composite system outperformed unmodified SIS and SIS scaffolds lacking BMSCs in terms of therapeutic efficacy. In vitro, PABS stimulated fibroblast proliferation, migration, and angiogenic activity, while enhancing type I and III collagen synthesis and modulating inflammatory cytokine expression. In vivo, it expedited wound closure, facilitated continuous epidermal regeneration, and increased collagen deposition in the dermal layer. Immunohistochemical analysis revealed enhanced neovascularization and reduced local inflammatory responses in the treated wounds. These results collectively suggest that this bioactive composite system creates a conducive structural and biochemical microenvironment supporting the healing of infected wounds. The SIS acts as a natural ECM scaffold that preserves collagen and glycosaminoglycans, facilitating cell attachment and infiltration8. Its interconnected porous structure and moderate degradation rate preserve permeability and mechanical strength, crucial characteristics of skin-repair hydrogels29. When combined with PLGA nanoparticles, SIS acts as a bioactive reservoir, establishing a stable microenvironment that enhances fibroblast proliferation and tissue remodeling24. BMSCs contribute to angiogenesis and regulation of inflammation through paracrine and exosomal signaling. Studies have shown that they release VEGF, HGF, and bFGF, which promote endothelial migration and tube formation30. These processes may elucidate the augmented vessel-like structures and heightened collagen deposition noted in the BMSC-containing groups. Additionally, BMSCs have been found to regulate NF-κB signaling, resulting in decreased expression of TNF-α and IL-61,31. AS-IV has been documented to function as an immunomodulatory and proangiogenic compound. It has been shown to inhibit NF-κB and MAPK signaling pathways32, while potentially activating PDGF-BB/PDGFR-β and PI3K/Akt signaling pathways33. In fibroblasts, AS-IV has been observed to upregulate COL1A1 and COL3A1 expression, possibly through TGF-β/Smad signaling pathways34,35. The sustained release of AS-IV from the PLGA nanoparticles may have contributed to their prolonged bioactivity, aligning with the gradual cellular responses observed in vitro. Overall, SIS provided structural support, BMSCs offered regenerative cues, and AS-IV delivered biochemical regulation, establishing an in vitro environment that facilitated fibroblast function, matrix formation, and inflammation balance. In this study, PABS created a favorable microenvironment for BMSCs, leading to enhanced angiogenesis, collagen synthesis, and inflammation regulation. These results indicate that the therapeutic effects observed may involve multiple signaling pathways, such as NF-κB–related inflammatory regulation and PI3K/Akt–associated angiogenesis, although further mechanistic validation is required36. Similar to previous ECM-based scaffolds, the SIS component offered a collagen-rich porous matrix that facilitated endothelial adhesion and migration36,37. However, unlike native SIS, the PLGA modification in our system enhanced mechanical stability and sustained bioactive release, ensuring more consistent support for cell growth. In line with previous research, AS-IV has been reported to regulate the synthesis of collagen I and III, potentially through the TGF-β/Smad signaling pathway, whereas SIS offers integrin-mediated signals that aid in fibroblast-driven matrix deposition38. The increased accumulation of ECM observed in this study implies a synergistic interplay between biochemical and structural components, surpassing the individual effects of each component39,40. The anti-inflammatory properties of PABS, as evidenced by reduced levels of TNF-α, IL-1β, and IL-6, along with elevated expression of IL-10 and TGF-β, align with earlier findings. Previous studies have shown that AS-IV might influence the TLR4/NF-κB and NLRP3-related pathways, while exosomes derived from MSCs are recognized for promoting the polarization of macrophages towards an M2 phenotype40. These findings suggest that PABS could potentially deliver a collective anti-inflammatory impact, setting it apart from traditional hydrogels that predominantly rely on passive anti-inflammatory mechanisms. In vivo, PABS achieved faster wound closure and improved tissue architecture compared with SIS- or BMSC-free controls. The enhanced angiogenesis and collagen deposition were consistent with previously reported AS-IV-associated activation of endothelial and fibroblast-related pathways41,42. However, the controlled VEGF expression and balanced neovascularization observed here suggest that PABS provides more stable vascular remodeling than earlier systems43,44. Collectively, these findings suggest that the combination of PLGA-modified SIS, AS-IV, and BMSCs offers a synergistic advantage over single-component or unmodified scaffolds by integrating structural, cellular, and biochemical repair cues for effective wound healing. Compared to standard wound dressings or unmodified SIS scaffolds, our approach offers several key advantages. First, PLGA enhances the mechanical strength and structural stability of the material. Second, astragaloside pre-treatment improved cell viability and paracrine signaling. Third, the combination produced synergistic antibacterial and pro-healing effects, promoting both infection control and tissue repair. Additional in vivo control groups, such as BMSCs alone or AS-IV–preconditioned BMSCs, were not included in this study. Although the in vitro results suggest individual contributions, further studies are required to dissect their independent effects in vivo. In addition, direct in vivo bacterial quantification (e.g., CFU analysis) was not performed in this study, which limited the direct evaluation of antibacterial efficacy. In clinical settings, infected wounds are typically associated with complex heterogeneous microbial populations. Therefore, future studies incorporating comprehensive bacterial analyses are necessary to fully evaluate the antibacterial performance of the system, as these benefits accelerate and improve wound healing efficiency. However, the specific molecular mechanisms underlying these effects were not directly investigated in the present study and require further experimental validation. Conclusion In this study, a bionic dressing comprised of AS-pretreated BMSCs was combined with PLGA nanoparticle-modified PABS. This multifunctional scaffold demonstrated favorable attributes, including even nanoparticle distribution, preserved collagen framework, enhanced tensile strength, and controlled degradation rate under physiological conditions. Functionally, PABS stimulated collagen I/III deposition and upregulated angiogenic regulators such as HIF-1α, Ang1, and VEGF, thereby enhancing vascular stability in vitro. It also promoted endothelial tube formation, accelerated cell migration, and modulated the inflammatory microenvironment by inhibiting iNOS, IL-1β, IL-6, and TNF-α, while increasing IL-10 and TGF-β expression. In vivo, PABS accelerated wound closure, increased epidermal thickness up to 154 μm, enhanced collagen deposition to 50%, stimulated neovascularization, adjusted VEGF for vessel maturation, and reduced TNF-α levels, ultimately promoting tissue regeneration in infected wound models. These results demonstrate that PABS scaffolds not only provide mechanical stability but also actively regulate the wound microenvironment, offering a promising therapeutic approach for infected wound repair. Nevertheless, this study has some limitations. The specific molecular mechanisms governing PABS-mediated regulation are still unclear. Future research should prioritize elucidating these pathways and validating PABS efficacy in large animals or chronic wound models to advance its clinical application in regenerative medicine. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2 Supplementary Material 3 Supplementary Material 3 Supplementary Material 4 Supplementary Material 4 Supplementary Material 5 Supplementary Material 5 Supplementary Material 6 Supplementary Material 6 Supplementary Material 7 Supplementary Material 7 Supplementary Material 7 Supplementary Material 7